News Details

IVERIC bio Announces Publication of GATHER1 Phase 3 Clinical Trial Results for Zimura® in Geographic Atrophy Secondary to Age-related Macular Degeneration, in Ophthalmology®, the Journal of the American Academy of Ophthalmology

About IVERIC bio, Inc.
  • NASDAQ: $ISEE
  • Notified: $4.83
  • 08:46 EDT

Price Chart